Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,604.50
Bid: 1,604.00
Ask: 1,604.50
Change: -5.50 (-0.34%)
Spread: 0.50 (0.031%)
Open: 1,611.50
High: 1,615.50
Low: 1,599.50
Prev. Close: 1,610.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 2-FTSE 100 reverses course to end lower on Imperial slump

Thu, 20th Feb 2020 09:32

* FTSE 100 down 0.3%, FTSE 250 up 0.1%

* Ex-dividend trading drags down main bourse

* Smith+Nephew, Moneysupermarket.com among notable gainers

* Virus cases in South Korea deter more rapid gains
(Recasts with market reversing course, updates share prices
throughout)

By Shashwat Awasthi and Muvija M

Feb 20 (Reuters) - London's FTSE 100 handed back earlier
gains to record losses on Thursday as a 7.3% fall in tobacco
giant Imperial Brands overshadowed a 10% leap in medical
products maker Smith+Nephew.

The blue-chip index slipped 0.3% as Imperial Brands
tumbled on ex-dividend trading, while most other sectors
also traded in the red with a surge in coronavirus infections in
South Korea stoking fears about a deepening health crisis.

Smith+Nephew hit an all-time high and helped limit
losses on the index after the medical products maker forecast
another year of revenue growth.

The FTSE 250 midcap index ended the day with a 0.1%
rise, led by a 19% surge in price comparison website
Moneysupermarket.com following upbeat outlook and a 7%
jump in engineering firm Spectris after 2019 results.

For the most part, the British indexes have drawn support
this week from stimulus measures from China, which cut its
benchmark lending rate to cushion the impact of the coronavirus
epidemic.

Both indexes are headed for a week of gains.

"Investors are making a number of significant assumptions
that governments and central banks will be able to mitigate the
effects of any disruption in the short and medium term," CMC
Markets analyst Michael Hewson said.

"Time will tell whether that is a safe assumption to make,
however in the absence of anywhere else to put one's money, the
line of least resistance for now appears to be to buy stocks."

Among other notable gainers on the main index were defence
firm BAE Systems and lender Lloyds with gains
of 3% and 1.4%, respectively, after their annual results.

However, the FTSE 100's losses were deepened by 1%-1.7%
falls in GlaxoSmithKline and Unilever, whose
stocks also traded without dividend entitlement.

Small-cap bathroom and kitchen products supplier Norcros
slid 11% after it warned annual profit would miss market
expectations and supply chain disruptions due to the coronavirus
outbreak would likely hit performance.
(Reporting by Shashwat Awasthi in Bengaluru; Editing by Shounak
Dasgupta, Saumyadeb Chakrabarty and Alison Williams)

More News
17 Jan 2024 07:31

GSK raises $1.24 bln from latest Haleon stake sale

Jan 17 (Reuters) - GSK has raised 978 million pounds ($1.24 billion) from a discounted sale of a stake in its spun-off consumer healthcare business Haleon, the British drugmaker said on Wednesday.

Read more
16 Jan 2024 17:04

GSK to sell GBP1 billion worth of Haleon shares as trims stake again

(Alliance News) - GSK PLC on Tuesday said it intends to sell around GBP1.00 billion worth of shares in Haleon PLC, as it continues to reduce its shareholding in the Weybridge, Surrey-based consumer healthcare spin-off.

Read more
16 Jan 2024 09:14

LONDON BROKER RATINGS: UBS raises GSK and cuts AstraZeneca

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
16 Jan 2024 08:15

UBS downgrades AstraZeneca to 'sell'

(Sharecast News) - UBS has downgraded AstraZeneca and upgraded rival GSK as part of its latest review of the European pharmaceutical sector.

Read more
16 Jan 2024 07:37

LONDON BRIEFING: UK jobless rate sticks at 4.2% but pay growth slows

(Alliance News) - Stocks in London are called to open lower on Tuesday, following data showing that the UK jobless rate was unchanged at 4.2% as pay growth slowed.

Read more
15 Jan 2024 08:42

Zantac fallout unfairly weighing on GSK, says Shore Capital

(Sharecast News) - Shore Capital has raised its target price and maintained a positive stance on biopharma giant GSK, saying that worries about the potential cost of Zantac litigation are unfairly weighing on the stock.

Read more
10 Jan 2024 09:35

LONDON BROKER RATINGS: BofA cuts Ashtead; UBS likes 3i Group

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
10 Jan 2024 08:25

GSK says Nucala gets green light in China for asthma treatment

(Alliance News) - GSK PLC on Wednesday said Nucala has been approved in China for the treatment of severe asthma.

Read more
10 Jan 2024 07:22

GSK's Nucala gets fresh approval in China

(Sharecast News) - GSK announced on Wednesday that the China National Medical Products Administration (NMPA) has granted approval for 'Nucala', or mepolizumab, as an add-on maintenance treatment for severe eosinophilic asthma in adults and adolescents aged 12 years and older.

Read more
9 Jan 2024 16:22

London close: Stocks finish red after choppy session

(Sharecast News) - London stocks had turned back into the red by the close on Tuesday, with recruitment firms and asset managers pacing the declines after some disappointing corporate updates.

Read more
9 Jan 2024 08:03

TOP NEWS: GSK to buy Aiolos Bio for up to USD1.4 billion

(Alliance News) - GSK PLC on Tuesday said it will acquire asthma drug developer Aiolos Bio Inc for USD1 billion upfront, as well as up to USD400 million in certain success-based milestone payments.

Read more
9 Jan 2024 07:16

GSK buys respiratory drug maker Aiolos for $1bn

(Sharecast News) - GSK said it was buying Aiolos, a clinical-stage biopharmaceutical company focused on treatment of respiratory and inflammatory conditions, for up to $1.4bn (£1.1bn).

Read more
8 Jan 2024 23:39

Pfizer to remain aggressive on obesity market after setback

NEW YORK, Jan 8 (Reuters) - Pfizer will remain aggressive in trying to break into the lucrative obesity market, even after dropping a high profile weight-loss drug candidate late last year due to strong side effects, Chief Executive Albert Bourla said on Monday.

Read more
8 Jan 2024 23:00

Pfizer to remain aggressive on obesity market after setback

NEW YORK, Jan 8 (Reuters) - Pfizer will remain aggressive in trying to break into the lucrative obesity market, even after dropping a high profile weight-loss drug candidate late last year due to strong side effects, Chief Executive Albert Bourla said on Monday.

Read more
8 Jan 2024 19:02

Moderna says it hit its 2023 COVID vaccine sales goal

Jan 8 (Reuters) - Moderna on Monday said its 2023 COVID vaccine sales would be around $6.7 billion, coming in above the lower end of its full-year forecast, and reiterated its goal of returning to sales growth in 2025.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.